Solid Biosciences Inc. develops precision genetic medicines for rare neuromuscular and cardiac diseases. The company’s recurring news centers on its gene therapy portfolio, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
Company updates also cover clinical data from Duchenne studies, regulatory designations for SGT-003, scientific presentations in gene and cell therapy, capital-raising activity, inducement equity grants, investor conference participation, shareholder voting matters, and governance disclosures.
Solid Biosciences (Nasdaq: SLDB) has announced the grant of an inducement award to Dr. Iman Barilero, the newly appointed Chief Regulatory Officer. This award consists of an option to purchase 180,000 shares at an exercise price of $3.75 per share, based on the closing stock price as of June 1, 2021. The option vests in four equal installments over four years, contingent upon Dr. Barilero's ongoing service with the company. Solid Biosciences focuses on developing therapies for Duchenne muscular dystrophy, targeting the underlying genetic mutation with its lead candidate, SGT-001.
Solid Biosciences (Nasdaq: SLDB) announced Dr. Iman Barilero as the new Chief Regulatory Officer, effective June 1, 2021. Dr. Barilero brings over 30 years of regulatory experience, having successfully guided numerous drug approvals in various global markets. She previously served as Senior Advisor to Innouvo and held key positions at Agenus, Poxel, and Lundbeck. Her expertise aligns with Solid’s mission to enhance therapies for Duchenne muscular dystrophy, particularly focusing on SGT-001 and SGT-003. The company aims to develop differentiated therapies through innovative regulatory strategies.
Solid Biosciences (Nasdaq: SLDB) announced that its COO, Joel Schneider, PhD, will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET. A live webcast will be accessible on the Company’s investor relations website, with a replay available after the event. Solid Biosciences focuses on developing therapies for Duchenne muscular dystrophy, specifically targeting the underlying mutations with its lead gene therapy candidate, SGT-001.
Solid Biosciences (Nasdaq: SLDB) announced participation in key scientific conferences focusing on Duchenne muscular dystrophy. At the 16th International Congress of Neuromuscular Diseases on May 21-22 & 28-29, Dr. Perry Shieh will present findings from the Phase I/II IGNITE DMD trial of SGT-001 microdystrophin gene therapy, highlighting long-term biopsy data and safety evaluations. Additionally, at the Gene Therapy for Muscular Disorders conference from May 25-27, Dr. Carl Morris will discuss drug development strategies and participate in expert panels.
Solid Biosciences (SLDB) provided an update on its Q1 2021 performance, with a net loss of $16.9 million, down from $26.7 million in Q1 2020. The company reported collaboration revenue of $3.3 million and ended the quarter with $268.5 million in cash, ensuring a cash runway into Q4 2022. In clinical updates, two additional patients were dosed in the IGNITE DMD trial, with a serious adverse event noted for patient 8. Long-term results showed durable microdystrophin expression from SGT-001, and the company announced advancements in its next-generation DMD gene therapy candidate, SGT-003.
Solid Biosciences (Nasdaq: SLDB) announced it will release its first quarter 2021 financial results before the market opens on May 14, 2021. A conference call will be held at 8:30 a.m. ET to discuss the financial results and recent business updates. The event can be accessed via a live webcast on the company's website, with an archived version available afterward. Solid Biosciences focuses on developing therapies for Duchenne muscular dystrophy, primarily through its lead gene therapy candidate, SGT-001.
Solid Biosciences (Nasdaq: SLDB) announced the presentation of three abstracts at the ASGCT 24th Annual Meeting, focusing on AAV vectors and the IGNITE DMD trial for SGT-001, a gene therapy for Duchenne muscular dystrophy. Key presentations include:
- AAV9 immune response mechanisms.
- Characterization of novel AAV vectors for muscle gene delivery.
- 12-month data from the IGNITE DMD Phase I/II trial of SGT-001, scheduled for May 14, 2021.
SGT-001 aims to address the genetic causes of Duchenne by delivering a synthetic dystrophin gene.
Solid Biosciences (Nasdaq: SLDB) announced participation in a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit on April 27, 2021, at 10:30 am ET. Joel Schneider, COO, and Louise Perry, Head of Technical Operations, will discuss advancements in therapies for Duchenne muscular dystrophy.
A live webcast will be available on the Company's investor relations website, and a replay can be accessed afterwards.
Solid Biosciences (Nasdaq: SLDB) announced that Dr. Carl Morris, Chief Scientific Officer, will participate in a panel discussion on Duchenne muscular dystrophy (DMD) at the virtual Guggenheim Healthcare Talks on April 1, 2021, from 9:00 a.m. to 9:50 a.m. EDT. The panel, titled “The more we learn the less we know about DMD,” will explore advancements in DMD therapies. A live webcast of the event will be available on the company’s investor relations website, with a replay accessible afterward.
Solid Biosciences (Nasdaq: SLDB) announced the closing of an underwritten public offering of 25 million shares of common stock at $5.75 each, generating approximately $143.8 million in gross proceeds. This offering included 3.26 million shares from the underwriters' option to purchase additional shares. Jefferies, SVB Leerink, and Piper Sandler were the joint book-running managers for the offering. The shares were issued under an effective shelf registration statement, filed with the SEC on March 13, 2019, and declared effective on March 19, 2019.